ExSight Ventures Backs RevOpsis Therapeutics' Novel Tri-Specific Antibody Platform for Retinal Diseases
Key Insights
ExSight Ventures (search) has invested in RevOpsis Therapeutics (search) to advance the company's novel multispecific antibody-based treatments for wet age-related macular degeneration (search) and diabetic eye disease (search).
RevOpsis' lead candidate RO-104 is a first-in-class fully human modular tri-specific biologic targeting all three clinically validated angiogenic pathways (VEGF-A (search), VEGF-C (search), Ang-2 (search)) in retinal vascular diseases.
The funding will accelerate preclinical development of RO-104 and expand RevOpsis' pipeline of ophthalmic assets using their proprietary Rev-Mod platform.
ExSight Ventures (search), a venture capital firm focused on ophthalmology innovations, has announced its investment in RevOpsis Therapeutics (search), a biotechnology company developing next-generation therapies for retinal diseases. The funding will enable RevOpsis to accelerate preclinical development of its lead candidate and expand its pipeline of novel ophthalmic assets.
Revolutionary Tri-Specific Approach
RevOpsis is pioneering a novel class of multispecific antibody-based treatments designed to address significant unmet needs in ophthalmology, with initial focus on wet age-related macular degeneration (search) (AMD) and diabetic eye disease (search). The company's proprietary Rev-Mod platform integrates advanced protein engineering with validated biological pathways to deliver therapies that aim to improve durability, efficacy, and patient outcomes.
The company's lead candidate, RO-104, represents a significant advancement in retinal disease treatment. Engineered as a first-in-class fully human modular tri-specific biologic, RO-104 is designed to address all three clinically validated dominant angiogenic pathways (VEGF-A (search), VEGF-C (search), Ang-2 (search)) implicated in retinal vascular disease (search) progression, including neovascular age-related macular degeneration (search) (nAMD).
Strategic Partnership and Validation
"We are thrilled to support RevOpsis in its mission to bring breakthrough therapies to patients suffering from vision-threatening conditions," said Firas Rahhal, MD, General Partner at ExSight Ventures (search) and Retina Vitreous Associates Medical Group (search) in Los Angeles. "Our investment reflects our strong belief in both the scientific foundation of RevOpsis' platform and the experienced leadership team driving its development."
Ram Bhandari, MD, Chief Executive Officer and Co-founder of RevOpsis Therapeutics (search), emphasized the significance of this partnership. "ExSight Ventures (search) is a leading investor in the ophthalmology space, and their support is a strong validation of our approach," he said. "This partnership will help us advance our pipeline toward clinical development and bring us closer to providing patients with more effective and longer-lasting treatment options."
Company Background and Platform
Founded in 2018, RevOpsis Therapeutics (search) is a privately held, next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies. The company is guided by a team of leading physicians, scientists, and business leaders, and is dedicated to leveraging its proprietary Rev-Mod Platform to develop and commercialize groundbreaking treatments for chronic multifactorial diseases.
ExSight Ventures (search) is a venture capital firm built to serve early-stage life sciences, with deep clinical expertise and venture discipline. The firm stands as trusted partners for innovators transforming ophthalmology, with a commitment to backing pioneering teams advancing breakthrough innovations to patients who need them most.
Future Development Plans
The investment will enable RevOpsis to accelerate the preclinical development of RO-104 and expand its pipeline of novel ophthalmic assets. Bhandari noted that ExSight Ventures (search) has a proven track record of backing companies developing innovative solutions in eye care, and this investment further demonstrates the firm's commitment to supporting the next wave of therapeutic breakthroughs in ophthalmology.
With a steadfast commitment to responsibly advancing patient care, RevOpsis aims to usher in a new era of improved disease management and extended disease remission for patients with retinal vascular diseases.